Good evening :)
Kilitch Drugs (India) Ltd

Kilitch Drugs (India) Ltd

KILITCH Share Price

NSE
₹316.751.06% (-3.40)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health Care
PharmaceuticalsDipak Kanayalal Shah PortfolioSharad Kanayalal Shah Portfolio
Smallcap

With a market cap of ₹553 cr, stock is ranked 1,793

High Risk

Stock is 3.33x as volatile as Nifty

KILITCH Stock Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

Avg

Financials growth has been moderate for a few years

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health Care
PharmaceuticalsDipak Kanayalal Shah PortfolioSharad Kanayalal Shah Portfolio
Smallcap

With a market cap of ₹553 cr, stock is ranked 1,793

High Risk

Stock is 3.33x as volatile as Nifty

KILITCH Performance & Key Metrics

KILITCH Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
21.272.76—
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
36.935.820.58%

KILITCH Analyst Ratings & Forecast

—
Analyst Ratings data is currently unavailable for this stock

Price Upside

Earnings Growth

Rev. Growth

KILITCH Company Profile

Kilitch Drugs (India) Limited is engaged in the development and operations of pharmaceutical business. The Company's services range from manufacturing to marketing a host of formulations in solid, liquid and parenteral forms.

KILITCH Similar Stocks (Peers)

Compare with peers Compare with peers 

KILITCH Similar Stocks (Peers)

Compare with peers Compare with peers 
Sun Pharmaceutical Industries Ltd
SUNPHARMA
PE Ratio
39.80
39.80
1Y Return
12.49%
12.49%
Buy Reco %
94.29
94.29
Torrent Pharmaceuticals Ltd
TORNTPHARM
PE Ratio
78.41
78.41
1Y Return
44.18%
44.18%
Buy Reco %
81.48
81.48
Dr Reddy's Laboratories Ltd
DRREDDY
PE Ratio
19.35
19.35
1Y Return
17.35%
17.35%
Buy Reco %
51.61
51.61
Cipla Ltd
CIPLA
PE Ratio
20.43
20.43
1Y Return
8.84%
8.84%
Buy Reco %
54.84
54.84
Lupin Ltd
LUPIN
PE Ratio
32.55
32.55
1Y Return
16.27%
16.27%
Buy Reco %
72.22
72.22
Compare with Peers

KILITCH Sentiment Analysis

KILITCH Sentiment Analysis

New
Crisp summary & key insights to decode earnings calls instantly

KILITCH Stock Summary · June 2024

Kilitch Drugs India Limited is strategically positioned for growth, particularly in the Ethiopian market, where it holds a unique competitive advantage as the sole supplier of Cephalosporin. Despite facing challenges with declining standalone revenue in Q4 FY24, the company anticipates a robust year-on-year growth of 25%-30% for FY25, bolstered by significant government contracts and an expanding product portfolio. Operational enhancements, including a new manufacturing facility in Khopoli and increased capacity at the Mumbai plant, are expected to drive efficiency and revenue. The proactive approach to working capital management, coupled with a focus on regulatory compliance, underscores the company's commitment to sustaining stakeholder confidence and optimizing financial performance. Overall, the sentiment remains optimistic, reflecting confidence in future revenue generation and market expansion.

KILITCH Stock Growth Drivers
KILITCH Stock Growth Drivers
7
  • Expansion of Manufacturing Capabilities

    Kilitch Drugs India Limited has successfully expanded its manufacturing capabilities, including the establishment of a

  • Successful International Business Growth

    The company has achieved significant growth in its international business, securing new product approvals and

KILITCH Stock Challenges
KILITCH Stock Challenges
3
  • Decline in Q4 Financial Performance

    In Q4 FY 2023-24, the company reported a decline in standalone total operating revenue, which

  • Mixed Annual Financial Results

    For the full financial year 2023-24, while the company saw an increase in total operating

KILITCH Forecast

KILITCH Forecasts

empty forecast

Forecast data is currently unavailable

Forecast data is currently unavailable

Price

Price Upside

Revenue

Revenue Growth

Earnings

Earnings Per Share

KILITCH

KILITCH

Income

Balance Sheet

Cash Flow

KILITCH Income Statement

KILITCH Income Statement

Loading...

Quartersep 2023dec 2023mar 2024jun 2024sep 2024dec 2024mar 2025jun 2025sep 2025dec 2025
Total Revenue41.6934.7545.2936.0352.6457.8962.9245.7055.5855.34
Operating & Other expensessubtract32.5829.5137.7431.7941.3847.4346.6339.8843.8847.66
Depreciation/Amortizationsubtract0.820.810.930.850.610.810.850.840.860.94
Interest & Other Itemssubtract1.511.601.321.730.311.401.601.531.441.15
Taxes & Other Itemssubtract2.04-0.091.710.311.722.293.450.431.211.16
EPS2.871.812.190.815.253.636.331.844.972.50
See Costs

EPS in ₹. Other numbers in ₹ cr

KILITCH Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2025FY 2025

Annual report

PDF
FY 2024FY 2024

Annual report

PDF
FY 2023FY 2023

Annual report

PDF
FY 2022FY 2022

Annual report

PDF
FY 2021FY 2021

Annual report

PDF
FY 2020FY 2020

Annual report

PDF
FY 2019FY 2019

Annual report

PDF
FY 2018FY 2018

Annual report

PDF
FY 2017FY 2017

Annual report

PDF
 

KILITCH Stock Peers

KILITCH Past Performance & Peer Comparison

KILITCH Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Valuation

Technical

Forecast

ScreenerCompare valuation on Screener

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Kilitch Drugs (India) Ltd20.732.76—
Sun Pharmaceutical Industries Ltd39.806.000.88%
Torrent Pharmaceuticals Ltd78.4119.740.72%
Dr Reddy's Laboratories Ltd19.353.230.61%

KILITCH Stock Price Comparison

Compare KILITCH with any stock or ETF
Compare KILITCH with any stock or ETF
KILITCH
Loading...

KILITCH Holdings

KILITCH Shareholdings

KILITCH Promoter Holdings Trend

KILITCH Promoter Holdings Trend

Decreased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has decreased by 5.46%

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

KILITCH Institutional Holdings Trend

KILITCH Institutional Holdings Trend

Increased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has increased by 1.34%

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

KILITCH Shareholding Pattern

KILITCH Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding63.77%0.00%0.00%0.00%36.23%

Mar 2025

Jun 2025

Sep 2025

Dec 2025

KILITCH Shareholding History

KILITCH Shareholding History

SepDec '24MarJunSepDec '250.00%0.00%0.00%0.00%0.00%0.00%

KILITCH Insider Trades & Bulk Stock Deals

KILITCH Insider Trades & Bulk Stock Deals

Loading...

smallcases containing KILITCH stock

smallcases containing KILITCH stock

Looks like this stock is not in any smallcase yet.

KILITCH Events

KILITCH Events

KILITCH Dividend Trend

No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year

KILITCH has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

KILITCH Dividend Trend

No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year

KILITCH has not given any dividends in last 5 years

KILITCH Upcoming Dividends

KILITCH Upcoming Dividends

No upcoming dividends are available

KILITCH Past Dividends

KILITCH Past Dividends

Cash Dividend

Ex DateEx DateSep 20, 2019

Final
Final | Div/Share: ₹0.50

Dividend/Share

₹0.50

Ex DateEx Date

Sep 20, 2019

Cash Dividend

Ex DateEx DateSep 18, 2018

Final
Final | Div/Share: ₹0.50

Dividend/Share

₹0.50

Ex DateEx Date

Sep 18, 2018

Cash Dividend

Ex DateEx DateSep 24, 2012

Special
Special | Div/Share: ₹30.00

Dividend/Share

₹30.00

Ex DateEx Date

Sep 24, 2012

Cash Dividend

Ex DateEx DateAug 18, 2011

Final
Final | Div/Share: ₹1.00

Dividend/Share

₹1.00

Ex DateEx Date

Aug 18, 2011

Cash Dividend

Ex DateEx DateOct 14, 2010

Final
Final | Div/Share: ₹1.00

Dividend/Share

₹1.00

Ex DateEx Date

Oct 14, 2010

KILITCH Stock News & Opinions

KILITCH Stock News & Opinions

Corporate
Kilitch Drugs (India) schedules EGM

Kilitch Drugs (India) announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 13 March 2026.Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Earnings
Kilitch Drugs (India) consolidated net profit declines 25.67% in the December 2025 quarter

Net profit of Kilitch Drugs (India) declined 25.67% to Rs 4.43 crore in the quarter ended December 2025 as against Rs 5.96 crore during the previous quarter ended December 2024. Sales declined 4.20% to Rs 53.81 crore in the quarter ended December 2025 as against Rs 56.17 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales53.8156.17 -4 OPM %11.4315.54 - PBDT6.539.06 -28 PBT5.608.25 -32 NP4.435.96 -26 Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Corporate
Kilitch Drugs (India) announces board meeting date

Kilitch Drugs (India) will hold a meeting of the Board of Directors of the Company on 11 February 2026.Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Kilitch Drugs (India) consolidated net profit declines 4.99% in the September 2025 quarter

Net profit of Kilitch Drugs (India) declined 4.99% to Rs 8.19 crore in the quarter ended September 2025 as against Rs 8.62 crore during the previous quarter ended September 2024. Sales rose 3.05% to Rs 48.92 crore in the quarter ended September 2025 as against Rs 47.47 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales48.9247.47 3 OPM %10.3012.85 - PBDT10.2610.95 -6 PBT9.4010.35 -9 NP8.198.62 -5 Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Kilitch Drugs (India) to conduct board meeting

Kilitch Drugs (India) will hold a meeting of the Board of Directors of the Company on 13 November 2025.Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Kilitch Drugs (India) AGM scheduled

Kilitch Drugs (India) announced that the 33rd Annual General Meeting(AGM) of the company will be held on 26 September 2025.Powered by Capital Market - Live

6 months agoCapital Market - Live
Earnings
Kilitch Drugs (India) consolidated net profit rises 126.12% in the June 2025 quarter

Net profit of Kilitch Drugs (India) rose 126.12% to Rs 3.03 crore in the quarter ended June 2025 as against Rs 1.34 crore during the previous quarter ended June 2024. Sales rose 28.97% to Rs 43.14 crore in the quarter ended June 2025 as against Rs 33.45 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales43.1433.45 29 OPM %7.564.96 - PBDT4.292.50 72 PBT3.451.65 109 NP3.031.34 126 Powered by Capital Market - Live

6 months agoCapital Market - Live
Corporate
Kilitch Drugs (India) to announce Quarterly Result

Kilitch Drugs (India) will hold a meeting of the Board of Directors of the Company on 13 August 2025.Powered by Capital Market - Live

7 months agoCapital Market - Live
Corporate
Kilitch Drugs (India) to convene board meeting

Kilitch Drugs (India) will hold a meeting of the Board of Directors of the Company on 2 July 2025.Powered by Capital Market - Live

8 months agoCapital Market - Live
Earnings
Kilitch Drugs (India) consolidated net profit rises 189.69% in the March 2025 quarter

Net profit of Kilitch Drugs (India) rose 189.69% to Rs 10.40 crore in the quarter ended March 2025 as against Rs 3.59 crore during the previous quarter ended March 2024. Sales rose 36.61% to Rs 61.23 crore in the quarter ended March 2025 as against Rs 44.82 crore during the previous quarter ended March 2024. For the full year,net profit rose 82.88% to Rs 26.70 crore in the year ended March 2025 as against Rs 14.60 crore during the previous year ended March 2024. Sales rose 28.47% to Rs 198.32 crore in the year ended March 2025 as against Rs 154.37 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales61.2344.82 37 198.32154.37 28 OPM %23.8315.80 -15.8715.64 - PBDT14.696.23 136 37.5822.70 66 PBT13.845.30 161 34.4719.35 78 NP10.403.59 190 26.7014.60 83 Powered by Capital Market - Live

9 months agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. What is the share price of Kilitch Drugs (India) Ltd (KILITCH) today?

    The share price of KILITCH as on 10th March 2026 is ₹316.75. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Kilitch Drugs (India) Ltd (KILITCH) share?

    The past returns of Kilitch Drugs (India) Ltd (KILITCH) share are
    • Past 1 week: 0.54%
    • Past 1 month: -14.42%
    • Past 3 months: -5.56%
    • Past 6 months: -13.68%
    • Past 1 year: 5.40%
    • Past 3 years: 144.10%
    • Past 5 years: 280.12%

  3. What are the peers or stocks similar to Kilitch Drugs (India) Ltd (KILITCH)?

    The peers or stocks similar to Kilitch Drugs (India) Ltd (KILITCH) include:

  4. What is the market cap of Kilitch Drugs (India) Ltd (KILITCH) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Kilitch Drugs (India) Ltd (KILITCH) is ₹553.70 Cr as of 10th March 2026.

  5. What is the 52 week high and low of Kilitch Drugs (India) Ltd (KILITCH) share?

    The 52-week high of Kilitch Drugs (India) Ltd (KILITCH) is ₹500 and the 52-week low is ₹293.53.

  6. What is the PE and PB ratio of Kilitch Drugs (India) Ltd (KILITCH) stock?

    The P/E (price-to-earnings) ratio of Kilitch Drugs (India) Ltd (KILITCH) is 20.73. The P/B (price-to-book) ratio is 2.76.

  7. Which sector does Kilitch Drugs (India) Ltd (KILITCH) belong to?

    Kilitch Drugs (India) Ltd (KILITCH) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  8. How to buy Kilitch Drugs (India) Ltd (KILITCH) shares?

    You can directly buy Kilitch Drugs (India) Ltd (KILITCH) shares on Tickertape. Simply sign up, connect your demat account and place your order.